| Literature DB >> 25075194 |
Bente Thoft Jensen1, Jørgen Bjerggaard Jensen1, Sussie Laustsen2, Annemette Krintel Petersen3, Ingrid Søndergaard4, Michael Borre1.
Abstract
PURPOSE: Health related quality of life (HRQoL) is an important outcome in cancer care, although it is not well reported in surgical uro-oncology. Radical cystectomy (RC) with lymph-node dissection is the standard treatment of muscle-invasive bladder cancer and high-risk noninvasive bladder cancer. A wide range of impairments are reported postsurgery. The aims were to evaluate whether a standardized pre- and postoperative physical exercise program and enhanced mobilization can impact on HRQoL and inpatient satisfaction in RC, as defined by the European Organisation for Research and Treatment of Cancer (EORTC).Entities:
Keywords: bladder cancer; health-related quality of life; patient-reported outcome (PRO); physical exercise; rehabilitation
Year: 2014 PMID: 25075194 PMCID: PMC4106955 DOI: 10.2147/JMDH.S62172
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
Figure 1CONSORT (Consolidated Standards of Reporting Trials) flowchart. Efficacy of a rehabilitation program in patients undergoing radical cystectomy, Aarhus University Hospital, 2011–2013.
Notes: Adapted from Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.48 The “÷” symbol signifies no cystectomy.
The exercise-based rehabilitation program. Efficacy of a multidisciplinary rehabilitation program for patients undergoing radical cystectomy, Aarhus University Hospital, 2011–2013, Denmark
| Preoperative outpatient optimization from inclusion to surgery (−14 days) | Postoperative in-hospital optimization Day 0–7+ |
|---|---|
| Information | Mobilization |
| Exercise-based prehabilitation program | Exercise-based rehabilitation program |
| Follow-up | Follow-up |
Abbreviation: MDT, multidisciplinary team.
Intervention compared to standard fast track (FT). Efficacy of a multidisciplinary rehabilitation program for patients undergoing radical cystectomy. Aarhus University Hospital, 2011–2013, Denmark
| Intervention FT, n= 50 | Standard FT, n=57 | |
|---|---|---|
| Preoperative (2 weeks prior to surgery) | Prehabilitation (exercise program) | • Nutritional screening and counseling, supportive oral supplements when recommended |
| Perioperative | • Infection prophylaxis (single doses) | • Infection prophylaxis (single doses) |
| Postoperative | Postrehabilitation (exercise program and enhanced mobilization) | • Analgesia within the first 72 hours – subfascial Pain-buster providing continuous infusion of bupivacaine; peripheral pain treatment – oral paracetamol |
| Discharge | Standardized discharge criteria | |
Clinical and demographic covariates in 107 patients undergoing radical cystectomy at Aarhus University Hospital (Denmark), 2011–2013. To analyze and test for statistical differences between groups, the following tests were used: rank-sum test (Wilcoxon) for categorical variables, Pearson’s two-sided χ2 test for proportions, and Student’s t-test for continuous variables
| Intervention | Standard | Difference | ||
|---|---|---|---|---|
| Sex | 0.38 | |||
| Men, n (%) | 39 (78) | 40 (70) | ||
| Women, n (%) | 11 (22) | 17 (30) | ||
| Age, years | 0.48 | |||
| Mean (95% CI) | 69 (66–72) | 71 (68–73) | −2 (−5.0 to 2.4) | |
| Range | 46–85 | 47–91 | ||
| Maximum tumor stage, n (%) | 0.57 | |||
| T1 | 10 (20) | 14 (25) | ||
| T2 | 29 (58) | 25 (44) | ||
| T3 | 10 (20) | 14 (24) | ||
| T4 | 1 (2) | 4 (7) | ||
| Urinary diversion, n (%) | 0.61 | |||
| Ileal conduit | 44 (88) | 48 (84) | ||
| Orthotopic neobladder | 5 (10) | 7 (12) | ||
| Continent cutaneous reservoir | 1 (2) | 2 (4) | ||
| Surgical procedure, n (%) | 0.64 | |||
| Open surgery | 41 (82) | 44 (77) | ||
| Robot-assisted | 9 (18) | 13 (23) | ||
| Time (minutes) for surgical procedure | ||||
| Open surgery, mean (95% CI) | 257 (232–282) | 258 (236–281) | −1 (−35 to 32) | 0.90 |
| Robot-assisted, mean (95% CI) | 448 (341–555) | 426 (392–461) | 22 (−67 to 111) | 0.60 |
| Transfer pack SAG-M, mean (95% CI) | 3.24 (2.47–4.01) | 2.69 (2.0–3.41) | 0.50 (−0.49 to 1.6) | 0.30 |
| Pain, VAS 1–10, n (%) | 0.22 | |||
| 0, n (%) | 36 (72) | 45 (79) | ||
| 1–3 | 6 (12) | 8 (14) | ||
| 4–5 | 5 (10) | 4 (7) | ||
| ≥6 | 3 (6) | 0 | ||
| Comorbidity index score (age-adjusted), n (%) | 0.82 | |||
| 0, no comorbidity | 1 (2) | 0 | ||
| 1–2, low | 16 (32) | 14 (25) | ||
| 3–4, high | 23 (46) | 31 (54) | ||
| ≥5, severe | 10 (20) | 12 (21) | ||
| Nutritional risk score (NRS 2002), n (%) | 0.26 | |||
| ≥3, at risk | 14 (28) | 9 (16) | ||
| <3 | 36 (72) | 48 (84) | ||
| Body mass index | 0.77 | |||
| Mean (95% CI) | 26 (25–27) | 26 (25–27) | 0 (−2 to 1) | |
| Nutritional intake (preoperative) | ||||
| Energy (kJ), mean (95% CI) | 8897 (8,294–9,501) | 8,818 (8,111–9,986) | −79 (−846 to 1,004) | 0.85 |
| Protein (g), mean (95% CI) | 87 (81–93) | 86 (82–92) | −6 (−7 to 10) | 0.76 |
| Bowel function (Bristol 1–6) | 0.25 | |||
| 1–3 | 11 (22) | 15 (25) | ||
| 4–5 | 37 (74) | 39 (65) | ||
| ≥6 | 2 (4) | 3 (10) | ||
| Smoker, n (%) | 0.38 | |||
| Never | 10 (20) | 9 (16) | ||
| <5 years | 16 (32) | 12 (21) | ||
| ≥5 years | 5 (10) | 15 (26) | ||
| Present | 15 (30) | 18 (32) | ||
| Missing | 4 (8) | 3 (5) | ||
| Marital status, n (%) | 0.56 | |||
| Living with a partner | 31 (62) | 32 (56) | ||
| Living alone | 16 (32) | 21 (37) | ||
| Missing | 3 (6) | 4 (7) | ||
Abbreviations: CI, confidence interval; SAG-M, saline, adenine, glucose, mannitol; VAS, visual analog scale; T, tumor.
Health-related quality of life (HRQoL) according to the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the disease-specific EORTC BLS24 (at baseline) and BLM30 (at follow-up) in 107 patients undergoing radical cystectomy at Aarhus University Hospital, 2011–2013.
| Intervention Difference % (95% CI) Follow-up to baseline nI=50 | Standard Difference % (95% CI) Follow-up to baseline nS=57 | Difference (95% CI) | ||
|---|---|---|---|---|
| Overall HRQoL (score 0–100), % | ||||
| Global health status | 1.8 (−5.2 to 8.7) | 4.2 (−4.0 to 12.3) | −2.4 (−13.2 to 8.4) | 0.60 |
| Functional scales (score 0–100), % | ||||
| Physical functioning | −6.8 (−13.3 to −0.4) | −4.4 (−7.9 to −0.9) | −2.4 (−9.3 to 4.6) | 0.59 |
| Role functioning | −10.2 (−23.3 to 2.9) | 0.3 (−10.4 to −10.9) | −10.5 | 0.11 |
| Emotional functioning | 7.1 (−0.5 to 14.8) | 11.3 (5.7–16.9) | −4.2 | 0.35 |
| Cognitive functioning | −4.4 (−12.0 to 3.0) | 1.6 (−5.3 to 3.2) | −6.1 | 0.37 |
| Social functioning | −7.3 (−15.2 to 0.6) | −5.9 (−11.7 to −0.1) | −1.4 (−10.9 to 8.0) | 0.93 |
| Symptom scales (score 0–100), % | ||||
| Fatigue | 7.3 (−2.5 to 17.2) | 0.9 (−5.9 to 7.7) | 6.5 | 0.18 |
| Nausea and vomiting | 0.8 (−7.1 to 8.7) | 7.5 (−3.9 to 3.9) | 0.8 (−7.5 to 9.1) | 0.36 |
| Pain | 0.8 (−9.8 to 11.4) | −1.3 (−7.8 to 5.2) | 2.1 (−9.7 to 13.9) | 0.73 |
| Dyspnea | −7.0 (−15.5 to 1.6) | 2.6 (−4.4 to 9.6) | −9.6 | 0.05 |
| Insomnia | 6.4 (−4.5 to 17.2) | −7.8 (−17.4 to 1.6) | 14.2 | 0.04 |
| Appetite loss | 0.8 (−9.4 to 10.9) | −2.0 (−11.2 to 7.3) | 2.7 (−10.8 to 16.3) | 0.78 |
| Constipation | 1.6 (5.7–8.8) | 14.4 (6.4–22.4) | −12.8 | 0.02 |
| Diarrhea | 1.6 (7.3–10.5) | 0.6 (1.0–7.3) | 0.9 (−9.8 to 11.7) | 0.81 |
| Disease-specific scales (BLM30, BLS24, score 0–100), % | ||||
| Future perspectives (worries) | −26.6 (−35.6 to −17.6) | −29.3 (−37.7 to 20.9) | 2.7 (−9.4 to 14.8) | 0.55 |
| Abdominal flatulence | 4.3 (−3.6 to 12.1) | 10.7 (3.0–18.3) | −6.4 | 0.05 |
| Sexual interest | 2.0 (−9.0 to 13.6) | −5.3 (−11.7 to 1.2) | 7.3 | 0.16 |
| Sexual activity | −4.4 (−15.0 to 6.9) | −10.5 (−18.2 to −2.8) | 7.4 (−6.4 to 19.4) | 0.47 |
| Single time point postsurgery (score 0–100), % | ||||
| Body image | 28.9 (19.7–37.9) | 19.1 (12.6–25.5) | 9.8 | 0.11 |
| Urinary problems (only neobladders) | 18.1 (5.3–30.9) | 38.3 (19.4–57.0) | −20 | 0.05 |
| Catheter problems (only neobladders) | 38.8 (−2.0 to 79.8) | 8.3 (−11.4 to 28.0) | 30.5 | 0.06 |
| Stoma problems (only ileal conduit) | 18.2 (12.75–23.8) | 13.5 (9.2–17.7) | 4.7 | 0.17 |
Notes: Increases in the function subscale scores represent an improvement in the HRQoL, whereas increases in the symptom subscale scores represent a deterioration. The null hypothesis was tested using the Wilcoxon signed-rank test.
P≤0.05;
clinically relevant difference in small–medium efficacy;
clinically relevant difference in large efficacy.
Abbreviation: CI, confidence interval; QLQ-C30, Quality of Life Questionnaire Core 30.
Inpatient satisfaction with treatment, care, and service measured at discharge using the European Organisation for Research and Treatment of Cancer (EORTC) IN-PATSAT32 in 107 patients undergoing radical cystectomy, Aarhus University Hospital, 2011–2013.
| Scales | Intervention score (95% CI) nI=50 | Standard score (95% CI) nS=57 | |
|---|---|---|---|
| Doctors (score 0–100) | |||
| Interpersonal skills | 85.0 (79.9–90.0) | 88.7 (84.5–92.8) | 0.26 |
| Technical skills | 85.7 (81.7–89.8) | 87.8 (83.9–91.7) | 0.45 |
| Information provisions | 82.3 (77.8–86.8) | 84.9 (79.9–89.8) | 0.44 |
| Availability | 76.2 (69.6–82.9) | 78.3 (73.5–83.08) | 0.62 |
| Nurses (score 0–100) | |||
| Interpersonal skills | 88.6 (84.2–93.1) | 88.6 (84.5–92.8) | 0.99 |
| Technical skills | 87.5 (83.1–91.89) | 86.7 (82.3–91.3) | 0.82 |
| Information provisions | 86.0 (81.9–90.1) | 83.5 (78.5–88.5) | 0.44 |
| Availability | 86.00 (81.3–90.6) | 81.4 (74.8–86.0) | 0.13 |
| Service (score 0–100) | |||
| Other personnel | 82.3 (77.8–86.8) | 81.4 (76.3–86.5) | 0.79 |
| Waiting time | 72.4 (66.2–78.7) | 72.1 (64.5–79.6) | 0.94 |
| Access | 59.2 (51.94–66.56) | 63.4 (57.56–69.32) | 0.37 |
| Single items (score 0–100) | |||
| Exchange of information | 79.0 (73.7–84.2) | 81.6 (75.8–87.3) | 0.13 |
| Comfort/cleanness | 63.5 (55.6–71.4) | 66.9 (59.8–74.1) | 0.51 |
| General satisfaction | 87.5 (83.1–91.8) | 87.7 (83.3–92.1) | 0.99 |
Notes: Linear scores (0–100 points) were calculated according to the EORTC manual. Statistically significant differences between groups were analyzed and tested using Student’s t-test.
Abbreviation: CI, confidence interval.